Daily Target 2X Long LLY ETF
LLYX
New York Stock Exchange Arca- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Defiance Daily Target 2X Long LLY ETF (LLYX) is an exchange-traded fund that seeks daily leveraged investment results of two times (200%) the daily percentage change in the share price of Eli Lilly and Company (NYSE: LLY), utilizing swap agreements and derivatives such as total return swaps with counterparties including Cantor, Marex, Nomura, BMO, and MS rather than direct investment in LLY shares; it maintains holdings in U.S. Treasury Bills and cash equivalents for collateral and liquidity. The fund targets sophisticated tactical traders seeking amplified short-term exposure to LLY's performance in the pharmaceutical sector, particularly amid innovations in GLP-1 receptor agonists for diabetes and weight loss, without requiring a margin account. LLYX operates in the U.S. market, listed on major exchanges with daily pricing and rebalancing to align with its leverage objective. Launched on August 8, 2024, by Defiance ETFs LLC, the fund sponsor established in 2018 and based in Miami, Florida, with Tidal Investments LLC serving as investment adviser, quickly grew assets under management to approximately $73 million as of late 2024. In September 2025, Defiance expanded its single-stock leveraged offerings with the launch of the complementary Defiance Daily Target 2X Short LLY ETF (LLYZ), providing inverse exposure to LLY and broadening tactical trading options around the underlying security. These developments position Defiance as a leader in leveraged single-stock ETFs focused on high-growth pharmaceutical names, emphasizing thematic opportunities in disruptive healthcare innovations.